Related Experiment Videos
Interactions between verapamil and metoprolol in the developing chick embryo heart
T Nishikawa1, T Kasajima, T Kanai
1Department of Pathology, Tokyo Women's Medical College, Japan.
Journal of Applied Toxicology : JAT
|April 1, 1991
Summary
Verapamil and metoprolol, when combined, caused heart defects in chick embryos. These cardiovascular malformations suggest altered calcium transport may be a cause.
Area of Science:
- Developmental biology
- Cardiovascular research
- Pharmacology
Background:
- Verapamil is a calcium channel blocker.
- Metoprolol is a beta-1 adrenergic receptor antagonist.
- These drugs are used to treat cardiovascular conditions.
Purpose of the Study:
- To investigate the teratogenic effects of verapamil and metoprolol, alone and in combination, on embryonic cardiovascular development.
- To explore potential causative factors for observed malformations.
Main Methods:
- Administration of verapamil and metoprolol to chick embryos at Hamburger-Hamilton stage 24.
- Assessment of cardiovascular malformations, including ventricular septal defects and aortic dextroposition.
- Evaluation of teratogenicity at different drug dosages.
Main Results:
- Neither verapamil nor metoprolol caused significant teratogenicity when administered alone.
- Combined administration of verapamil and metoprolol resulted in cardiovascular malformations.
- Observed defects included ventricular septal defects and overriding aorta.
Conclusions:
- Combined verapamil and metoprolol exposure induces cardiovascular malformations in developing chick embryos.
- Altered calcium myocyte transport and/or hemodynamic changes are potential causative mechanisms.
- This study highlights the potential risks of combined drug administration during critical developmental periods.